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indicate that N-truncated Aβ4-42 triggers acute and long-
lasting behavioral deficits comparable to AD typical mem-
ory dysfunction.
Keywords Pyroglutamate Abeta · Toxicity · Neuron loss · 
Degeneration · Transgenic mouse model · Spatial reference 
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Introduction
Alzheimer disease (AD) is a progressive neurodegen-
erative disorder characterized by the presence of extra-
cellular amyloid plaques composed of amyloid-β (Aβ) 
surrounded by dystrophic neurites and neurofibrillary tan-
gles. The discovery that certain early-onset familial forms 
of AD may be caused by an enhanced production of Aβ 
peptides led to the hypothesis that amyloidogenic Aβ is 
intimately involved in the AD pathogenic process [58]. 
Besides Aβ peptides starting with an aspartate at posi-
tion 1, a variety of different N-truncated Aβ peptides have 
been identified in AD brains. Ragged Aβ peptides, includ-
ing a major species beginning with phenylalanine at posi-
tion 4 of Aβ (Aβ4-42), have been reported as early as 1985 
by Masters et al. [33]. Among different Aβ species present 
in AD plaques, Lewis et al. [31] demonstrated that Aβ4-42 
is a relatively abundant species in AD, aged controls and 
vascular dementia patients. Using immunoprecipitation in 
combination with mass spectrometry, Portelius and col-
leagues [47] corroborated these earlier findings, reporting 
that Aβ4-42 is one of the major fractions in the hippocam-
pus and cortex of AD patients. It has been demonstrated 
that N-terminal deletions, including Aβ4-42, enhance Aβ 
aggregation [45] and that the N-terminus specifies fibrilli-
zation behavior [17].
Abstract N-truncated Aβ4-42 is highly abundant in Alz-
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cits assessed by the Morris water maze test. Our findings 
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There is increasing evidence that the primary insult in 
AD is caused by oligomeric species derived from full-
length Aβ1-42 impairing synaptic functions [14, 67]. In 
addition to soluble oligomers, β-sheet containing amyloid 
fibrils is also a highly toxic form of Aβ [16, 23, 59]. It has 
further been demonstrated that soluble oligomeric Aβ1-42, 
but not plaque-associated Aβ, correlates best with cogni-
tive dysfunction in AD [3, 30]. Numerous variants of Aβ1-42 
oligomers have been introduced and are currently being 
discussed as major factors in AD (reviewed in [3]). These 
include soluble Aβ1-42 dimers, trimers, tetramers and other 
variants, which have been demonstrated to be neuro- and/or 
synaptotoxic using cell or tissue culture models [29, 30, 43, 
60, 61]. It has been argued that a variety of low and high 
molecular weight soluble Aβ1-42 aggregates, rather than just 
one particular type of oligomer, could trigger neuronal dys-
function [34]. However, a consensus is lacking as to which 
types of Aβ structures, dynamics and bioactivities are the 
causal link to AD [51]. In addition to the numerous variants 
of Aβ1-42 oligomers currently being discussed [3], there is 
substantial evidence that N-terminal truncated peptides 
play a key role in AD [20].
The aim of the present work was to elucidate the struc-
ture of Aβ4-X aggregates and to study the potential acute 




The amyloid β (Aβ) variants Aβ4-38, Aβ4-40, Aβ4-42, AβpE3-42 
and Aβ1-42 were purchased from Peptide Specialty Labo-
ratory (PSL, Heidelberg, Germany) and used without fur-
ther purification. The peptide samples were prepared by 
first dissolving them in 1,1,1,3,3,3-hexafluoro-2-propanol 
(HFIP), flash-freezing in liquid nitrogen, and then lyophi-
lizing them to completely remove the solvent. Lyophilized 
Aβ peptides were then dissolved in 100 mM NaOH at a 
concentration of 2 mg/mL, aliquoted in 50 μL volumes, 
flash-frozen in liquid nitrogen and stored at −80 °C until 
use.
Thioflavin T (ThT) fluorescence measurement
Peptide samples of 40 μM concentration were prepared in 
HEPES buffer (25 mM, pH 7.4) containing 50 mM NaCl 
and 30 μM Thioflavin T (ThT). The kinetics of Aβ aggrega-
tion were then followed by real-time fluorescence emission 
measurement of ThT while the sample was kept at 37 °C 
and gently stirred. The excitation and emission wavelengths 
were 446 and 485 nm, respectively, with slits of 10 nm each.
Transmission electron microscopy (TEM)
Peptide samples of 0.1 mg/mL concentration in HEPES 
buffer (25 mM, pH 7.4, 50 mM NaCl) were incubated at 
37 °C with gentle stirring. After 3 days of incubation, sam-
ples were diluted, deposited onto carbon-coated copper 
mesh grids and negatively stained with 2 % (w/v) uranyl 
acetate. The excess stain was washed away, and the sam-
ple grids were allowed to air-dry. The samples were then 
viewed with a 120-kV transmission electron microscope.
Circular dichroism (CD) spectroscopy
Samples of 0.2 mg/mL peptide concentration in phosphate 
buffer (20 mM, pH 7.2) were prepared. The far-UV CD 
measurements were conducted on a Chirascan CD spec-
trometer, with a 1-mm path length quartz cell, 1-nm band-
width and 8-s collection time for each point at 0.5 nm steps 
between 190 and 260 nm. The buffer spectrum was also 
measured and subtracted from the spectra of Aβ peptides. 
The temperature-dependence of secondary structure was 
studied through far-UV measurements at three different tem-
peratures, 20, 30 and 40 °C. The reversibility of temperature-
induced changes was checked with an additional CD spec-
trum measured after cooling down from 40 to 20 °C. The CD 
spectrum of the cooled sample was taken after 5 min of equi-
libration at 20 °C. The 0.2 mg/mL Aβ samples in phosphate 
buffer (20 mM, pH 7.2) containing 25 mM NaCl were incu-
bated at 37 °C for 3 days with gentle stirring. Following ThT 
fluorescence measurements which confirmed the presence of 
ThT-reactive aggregates in the peptide samples, the far-UV 
CD spectra were obtained at 20 °C as described above.
Dynamic light scattering (DLS)
DLS experiments were performed at 20 °C on a DynaPro 
Titan (Wyatt Technology Corp., CA) instrument with a scat-
tering angle of 90°. The samples were centrifuged at 16,000g 
for 15 min, and then the supernatant was taken for DLS 
measurements. The “monomeric” samples were prepared 
freshly in phosphate buffer (20 mM, pH 7.4) containing 
25 mM NaCl at a peptide concentration of 0.2 mg/mL. The 
aggregated samples were prepared after incubation at 37 °C 
for 24 h, without further promotion of aggregation by agita-
tion. The size distribution was determined by a constrained 
regularization method. The reported scattering intensities are 
from three separate measurements of the same sample.
1D 1H nuclear magnetic resonance (NMR) monomer 
consumption assay
1D 1H NMR spectra of the five different Aβ peptides were 
measured at 5 °C at 400 MHz 1H Larmor frequency. The 
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samples contained 40-μM peptide in phosphate buffer 
(20 mM, pH 7.2) with 25-mM NaCl. The aggregation pro-
pensity of the Aβ variants were then studied through real-
time 1D 1H NMR experiments at 37 °C continued for 14 h 
at 1-h intervals. The integrated intensity of 1H peaks at two 
regions (0.50–1.05 ppm, 6.50–8.00 ppm), after chemical 
shift using DSS (4,4-dimethyl-4-silapentane-1-sulfonic 
acid) as a reference standard, was then calculated. After 
normalization by the integrated intensity of the DSS peak 
at 0 ppm, the relative intensity of the peptide 1H peaks was 
used to probe peptide monomer consumption during the 
early phases of peptide aggregation.
Western blot
Lyophilized Aβ peptides were dissolved in 10-mM NaOH 
at a concentration of 1 mg/mL, aliquoted in 50 μL vol-
umes, flash-frozen in liquid nitrogen and stored at −80 °C 
until use. For Western blot analysis under reducing con-
ditions, 1 μg peptides were loaded on 4–12 % VarioGels 
(Anamed), transferred to 0.45 μm nitrocellulose mem-
branes and detected using the primary antiserum 24311 
(pan-Aβ, 1:500) or monoclonal antibody 4G8 (Aβ17-24, 
Signet; 1:500). For Western blotting of mouse brain, whole 
brain SDS lysates were used. Running and transfer buffers 
were applied according to the manufacturer. The blots were 
developed using enhanced chemiluminescence according 
to the manufacturer (Roth). Horse radish conjugated swine 
anti-rabbit antibody was used as a secondary antibody 
(1:3,000, Dianova).
Neuronal culture
Cortical neurons from embryonic day 16–17 Wistar rat 
fetuses were prepared as previously described [46]. In 
brief, dissociated cortical cells were plated at 50,000 cells/
well in 48-well plates precoated with 1.5 mg/mL polyorni-
thine (Sigma). Cells were cultured in a chemically defined 
Dulbecco’s Modified Eagle’s/F12 medium free of serum 
(Gibco) and supplemented with hormones, proteins and 
salts. Cultures were kept at 35 °C in a humidified 5 % CO2 
atmosphere, and at 6–7 DIV, cortical population was deter-
mined to be at least 97 % neurons by immunostaining as 
done previously [71]. At 6 DIV, the medium was removed 
and cortical neurons were incubated for 24 h with vehicle 
(cell culture medium) or Aβ peptides (dissolved in cell cul-
ture medium) at the indicated concentrations.
Cell viability measurement
Following a 24-h incubation of primary cortical neurons 
with Aβ peptides, cell viability was determined using a 
calcein-AM assay (Invitrogen, Molecular Probes). Briefly, 
cells were washed twice with PBS and incubated to protect 
from light for 30 min at room temperature in the presence 
of 2 μM calcein-AM solution prepared in PBS. Cells were 
then washed twice with PBS and incubated for 15 min at 
room temperature in PBS containing 1 % Triton X-100 
(v/v). The level of calcein fluorescence was monitored by 
fluorescence emission at 530 nm after exciting at 485 nm, 
using a Fluostar microplate reader (BMG-Labtechnologies, 
France).
Intracerebroventricular injection of soluble Aβ
Male C57BL/6 J mice (12-week old, Janvier, Le Genest-
St-Isle, France; n = 6 per treatment group) were housed 
five to six per cage with free access to food and water, and 
were kept in a constant environment (22 ± 2 °C, 50 ± 5 % 
humidity, 12-h light cycle). Under anesthetization, freshly 
prepared Aβ peptides (50 pmol in 1 μL; 0.1 M phosphate-
buffered saline (pH 7.4)) or vehicle (0.1 M phosphate-buff-
ered saline) were injected into the right ventricle, with ster-
eotaxic coordinates from the bregma (AP −0.22, L −1.0 
and D 2.5 in mm). Intracerebroventricular (icv) injections 
were made using a 10-μl Hamilton microsyringe fitted with 
a 26-gauge needle. Four days following icv infusion of Aβ 
peptides, working memory was assessed using the Y-maze 
test.
Working memory by the Y-maze task
Immediate spatial working memory performance in male 
C57BL/6 J wildtype mice (12-week old, Janvier, Le 
Genest-St-Isle, France; n = 6 per treatment group) was 
assessed by recording spontaneous alternation behavior 
in a Y-maze as described previously [55, 71]. The Y-maze 
task was carried out on day 4 after soluble Aβ application. 
The maze was made of opaque plexiglas and each arm 
was 40-cm long, 16-cm high, 9-cm wide and positioned at 
equal angles. Mice were placed at the end of one arm and 
allowed to move freely through the maze during a 5-min 
session. The series of arm entries were recorded visually 
and arm entry was considered to be completed when the 
hind paws of the mouse were completely placed in the arm. 
Alternation was defined as successive entries into the three 
arms on overlapping triplet sets. The percentage alternation 
was calculated as the ratio of actual (total alternations) to 
possible alternations (defined as the number of arm entries 
minus two), multiplied by 100.
Generation of transgenic mice
The cDNA coding for Aβ4-42 was inserted into the Thy1 
expression construct and verified by sequencing. The trans-
genic founder mice were generated by male pronuclear 
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injection of fertilized C57BL/6 J oocytes. The resulting off-
spring were further characterized for transgene integration 
by PCR analysis, and after crossing to C57BL/6 J wildtype 
mice, for transgene expression by RT-PCR. Line 2, the line 
with highest transgene mRNA expression, was selected for 
further breeding (thereafter named Tg4-42). All animals 
were handled according to German guidelines for animal 
care. The mean age of the mice tested were 3 ± 1, 8 ± 1 
and 12 ± 1 months.
Immunohistochemistry and histology
Mice were killed via CO2 anesthetization followed by cer-
vical dislocation. Brain samples were carefully dissected 
and post-fixed in 4 % phosphate-buffered formalin at 4 °C. 
Immunohistochemistry was performed on 4-μm paraf-
fin sections. The following antibodies were used: 24311 
(1:500; rabbit polyclonal against pan-Aβ), Aβ42 (1:500; 
Synaptic Systems, rabbit polyclonal specific for the C-ter-
minus of Aβ42), synaptophysin (1:500; Synaptic Systems, 
monoclonal), GFAP (1:500; Chemicon), Iba1 (1:500; 
Waco). Biotinylated secondary anti-rabbit and anti-mouse 
antibodies (1:200) were purchased from DAKO. Staining 
was visualized using the ABC method, with a Vectastain 
kit (Vector Laboratories) and diaminobenzidine as chro-
mogen. Counterstaining was carried out with hematoxy-
lin. For DAPI staining sections were deparaffinized and 
washed in PBS followed by incubation in 4′,6-diamidine-
2′-phenylindole (DAPI, 1 μg/ml) for 1 min. Embedding 
was performed in aqueous fluorescent mounting medium 
(DAKO).
Quantification of neuron numbers using unbiased 
stereology
Mice were anaesthetized and transcardially perfused with 
4 % paraformaldehyde. Brains were carefully removed 
from the skull, post-fixed for 2 h and dissected. Stereologi-
cal analysis was performed as previously described [57]. 
Briefly, the left brain hemispheres were cryoprotected in 
30 % sucrose, quickly frozen and cut frontally into entire 
series of 30-μm thick sections on a cryostat (Microm 
HM550, Germany). Every tenth section was systematically 
sampled, stained with cresyl violet and used for stereolog-
ical analysis of the neuron number in the CA1. The hip-
pocampal cell layer CA1 and the striatum (CA1: Bregma 
−1.22 to −3.80 mm, striatum: Bregma 1.94 to −2.30 mm) 
were delineated on cresyl violet-stained sections. Using a 
stereology workstation [Olympus BX51 with a motorized 
specimen stage for automatic sampling, StereoInvestiga-
tor 7 (MicroBrightField, Williston, USA)] and a 100 × oil 
lens (NA = 1.35), neuronal nuclei were sampled ran-
domly using optical disector probes, and the total number 
of neurons was subsequently estimated by the fractiona-
tor method using a 2-μm top guard zone [66]. The hip-
pocampal cell layer CA1 of heterozygous Tg4-42 mice and 
wildtype (C57BL/6 J) littermate controls were analyzed at 
3, 8 and 12 months of age. In addition, the CA1 and stri-
atum of 8-month-old homozygous Tg4-42 (Tg4-42hom) 
were assessed. All groups were sex- and age-matched 
(n = 3–4 per group).
RNA extraction, cDNA synthesis and real-time PCR 
analysis (RT-PCR)
Mice were killed via CO anesthetization followed by cer-
vical dislocation. Mouse brains were rapidly dissected, 
frozen on dry ice and stored at −80 °C until use. Frozen 
brain hemispheres were homogenized in 1 ml of Trifast® 
reagent (Peqlab) per 100 mg tissue using a R50D homog-
enizer (10 strokes, 800 rpm; CAT). RNA extraction was 
performed according to the manufacturer’s protocol. RNA 
was reverse transcribed into cDNA using the First Strand 
cDNA Synthesis Kit (Fermentas GmbH). Quantitative real-
time RT-PCR was performed using a Stratagene MX3000P 
Real-Time Cycler. For quantification, the DyNamo Flash 
SYBR Green qPCR Kit containing ROX as an internal ref-
erence dye (Finnzymes, Finland) was used. Expression of 
the transgene was assessed with the following primer set, 
diluted to a concentration of 10 pmol/μL: 5′-TCCGGCCAG 
AACGTCGATTC-3′ (forward); 5′-GGAGAAGCAAGA 
CCTCTGC-3′ (reverse). A mixture of mouse β-actin prim-
ers (QuantiTect Primer Assays, Qiagen) served as a control. 
Statistical analysis of quantitative real-time PCR measure-
ments was done using the Relative Expression Software 
Tool V2.0.7 (REST 2008) [44].
Spatial reference memory by Morris water maze
Spatial reference memory in Tg4-42 mice was evaluated 
using the Morris water maze [39]. Thereby, mice learn 
to use spatial cues to locate a hidden, circular platform 
(10 cm) in a circular pool (110 cm diameter) filled with tap 
water. The water was made opaque by adding non-toxic 
white paint and maintained at 20 °C for the test duration. 
The pool was divided into four virtual quadrants that were 
defined based on their spatial relationship to the platform: 
left, right, opposite and target quadrants, which contain 
the goal platform. ANY-Maze video tracking software 
(Stoelting Co.,Wood Dale, USA) was used to record escape 
latency, path length, swimming speed and quadrant prefer-
ence. In order to test whether the groups differed regard-
ing their memory for the former location of the platform 
in the probe trial, we calculated for each mouse a platform 
quadrant preference ratio as follows: Time spent in Target 
Quadrant/(Time spent in Target Quadrant + Time spent 
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in Opposite Quadrant). Preference ratios close to 1 indi-
cate well, whereas ratios close to 0 indicate poor spatial 
memory.
Heterozygous Tg4-42 mice and wildtype (C57BL/6 J) 
littermate controls were tested at 3, 8 and 12 months of 
age. In addition, homozygous Tg4-42 (Tg4-42hom) mice 
were assessed at 3 and 8 months. All groups were sex- and 
age-matched (n = 10–15 mice per group). Each individual 
mouse was tested at one age only using the cued trials fol-
lowed by the acquisition training and finalized by the probe 
trial. After the probe trial, the mice were sacrificed. Test-
ing began with 3 days of cued training. For these trials, 
the platform was marked with a triangular flag. Mice were 
introduced into the water at the edge of the pool facing the 
wall. They were then given 1 min to find the submerged 
platform. Mice that failed to find the platform in 60 s 
were gently guided to it. All mice were allowed to sit on 
the platform for 10 s before being removed from the pool. 
To prevent hypothermia, all mice were kept in front of a 
heat lamp for 3 min before being returned to their home 
cage. Each mouse received four training trials per day with 
an average inter-trial interval of 15 min. Both the location 
of the platform and the position at which mice were intro-
duced into the pool changed between trials.
Twenty-four hours after the last day of cued training, 
mice performed 5 days of acquisition training. For this part 
of testing, the flag was removed from the platform. In addi-
tion to the distal cues existing in the room, proximal visual 
cues were attached to the outside of the pool. The platform 
location remained stationary for each mouse throughout 
training. At the start of every trial, mice were introduced 
into the pool from one of four predefined entry points. The 
order in which these entry points were used varied between 
training days [65]. To avoid quadrant bias, the experimental 
cohorts were randomly split and trained to find one of two 
different platform locations. Trials were conducted as dur-
ing the cued training phase.
Twenty-four hours after the last acquisition trial, a probe 
test was performed to assess spatial reference memory. The 
platform was removed from the pool, and mice were intro-
duced into the water from a novel entry point. Mice were 
then allowed to swim freely for 1 min while their swim-
ming path was recorded.
Statistical analysis
Differences between groups were tested with unpaired t 
test, one-way analysis of variance (ANOVA) followed by 
Bonferroni multiple comparison, two-way ANOVA or 
two-way repeated measures ANOVA followed by Bon-
ferroni multiple comparison or multivariate analysis of 
variance (MANOVA) as indicated. All data are given as 
mean ± standard error of the mean (SEM). Significance 
levels are given as follows: ***p < 0.001; **p < 0.01; 
*p < 0.05. All statistics were calculated using GraphPad 
Prism version 5.04 for Windows (GraphPad Software, San 
Diego, California, USA) and SPSS statistics version 17.0 
(IBM, Armonk, New York, USA).
Results
Aβ4-42 has a high aggregation propensity to form stable 
aggregates
The secondary structure of Aβ4-42 was investigated through 
far-UV CD spectroscopy. At 20 °C, the CD spectrum was 
characteristic of a disordered state. After temperature 
increase, Aβ4-42 showed reversible changes characterized 
by the loss of negative intensity at ~198 nm and accom-
panied with a red shift of the negative peak at ~220 nm. 
These spectral alterations indicated that Aβ4-42 has a high 
propensity to adopt a folded conformation upon heat-
ing (Fig. 1a). The comparison with other Aβ variants is 
shown in the supplement (Fig. S1–S3). In order to study 
the aggregation propensities of Aβ variants, we used NMR 
spectroscopy. For increasing incubation time, 1H signals 
were severely broadened beyond the detection limit of liq-
uid-state NMR. The temporal loss of signal intensity indi-
cates the conversion of NMR-visible monomers and small 
stable aggregates to large aggregates. As shown in Fig. 1b, 
the largest decreases in signal intensity were observed 
for AβpE3-42 and Aβ4-42, which lost ~30 and 20 % of their 
initial intensities, respectively, after 14 h of incubation at 
37 °C. Loss of signal intensity for Aβ1-42 and Aβ4-40 was 
around 5 %, while Aβ4-38 rose slightly in intensity. These 
data indicate the following order of aggregation propen-
sity among the five Aβ variants: AβpE3-42, Aβ4-42, Aβ1-42/
Aβ4-40 and Aβ4-38. The oligomerization propensities of the 
five Aβ peptides were then compared through light scatter-
ing intensity of the supernatants of the peptide solutions, 
before and after start of aggregation. Before aggregation, 
the highest scattering intensity was observed for Aβ4-42, 
followed by Aβ1-42, AβpE3-42, Aβ4-40 and Aβ4-38 (Fig. 1c). 
Upon aggregation, all peptides showed a prominent rise 
in the scattering intensity, reflecting a shift of their size 
distribution toward larger species. Aβ4-42 and AβpE3-42 
had the biggest intensities, followed by Aβ1-42 and Aβ4-40, 
then Aβ4-38. The scattering intensities of Aβ4-42 and AβpE3-42 
were mainly due to small aggregates of ~10 nm in hydro-
dynamic radius, with smaller but considerable contribu-
tions from 30 to 50 nm aggregates (Fig. 1d). On the other 
hand, Aβ1-42 contained small aggregates of 5–10 nm and a 
wide distribution of aggregates from 20 to 130 nm. Over-
all, Aβ4-42 and AβpE3-42, and to a lesser extent Aβ1-42, have 
a remarkable tendency to form stable aggregates. The 
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aggregates formed by Aβ4-42 and AβpE3-42 are distinct in 
size and different from Aβ1-42.
N-truncated Aβ variants rapidly aggregate and form fibrils
The fibrillar structure of Aβ aggregates, as revealed by 
transmission electron microscopy (TEM), is displayed 
in Fig. 2a. Temporal evolution of ThT emission intensity 
along Aβ aggregation is shown in Fig. 2b. Following lag 
phases of various durations, sharp rises in ThT emission 
intensity were observed for all Aβ variants. The maximal 
ThT intensities reached by the five peptides were similar, 
although all except Aβ1-42 started to decay afterwards. This 
is probably due to the burial of ThT-binding sites within 
higher order aggregate states or clumps. This hypothesis 
is supported by the TEM observations in which the four 
peptide variants, Aβ4-38, Aβ4-40, Aβ4-42 and AβpE3-42 often 
showed clumps of fibrillar aggregates. The observation that 
all peptides but Aβ1-42 formed clumps of fibrils points to 
the importance of the three N-terminal residues for aggre-
gate morphology.
N-truncated Aβ variants elicit stable aggregates
Freshly dissolved Aβ peptides, for which no specific pre-
cautions were taken for monomerization, were subjected to 
SDS-PAGE (Fig. 3a). Aβ1-42, AβpE3-42, and Aβ4-42 displayed 
monomers and aggregates most likely representing trimer/
tetramers, whereas Aβ4-38 and Aβ4-40 formed monomers, 
dimers but no other oligomers. After 1 and 3 days of aging, 
Aβ peptides displayed higher molecular weight oligom-
ers in addition for Aβ1-42, AβpE3-42, and Aβ4-42, but not for 
Aβ4-38 and Aβ4-40 (Fig. 3a). These Aβ preparations were 
used to study their acute effects on neuronal function and 
Fig. 1  Structural properties of N-terminally truncated Aβ. a Tem-
perature dependence of far-UV CD spectra of Aβ4-42. Measurements 
were performed at 20, 30 and 40 °C. 20 ° back indicates the measure-
ment after cooling down from 40 to 20 °C. b Rates of monomer con-
sumption for different Aβ peptides, probed through a decay in relative 
intensity of methyl (0.50–1.05 ppm) and aromatic (6.5–8.0 ppm) sig-
nals in their 1D 1H NMR spectra. c Excess light scattering intensity 
of Aβ variants measured before (solid bars) and after (striped bars) 
24 h of aggregation through dynamic light scattering (DLS). d Dis-
tribution of hydrodynamic radius (Rh) of Aβ aggregates, derived from 
their scattering intensity autocorrelation curve in DLS experiments. 
For Aβ4-42 and AβpE3-42, the main aggregated species had an Rh of 
approximately 10 nm
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Fig. 2  a Transmission electron micrograph of Aβ peptides after 
3 days of incubation in an aggregation-promoting condition. All Aβ 
variants formed fibrillar aggregates which tended to clump together 
in all preparations but Aβ1-42. b Temporal evolution of Thioflavin T 
(ThT) fluorescence emission intensity during aggregation of vari-
ous Aβ peptides. Despite some variation in the kinetics, all five Aβ 
variants were capable of forming ThT-reactive aggregates. Scale bars 
200 nm (Aβ4-42), 500 nm (all other Aβ variants)
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viability in vitro and in vivo by intraventricular injection 
into wildtype mouse brain.
N-truncated Aβ variants are toxic in vitro
In vitro toxicity was studied in primary neurons using a cal-
cein assay. Treating the cells with freshly prepared Aβ4-38, 
Aβ4-40, Aβ4-42, AβpE3-42 and Aβ1-42 resulted in a dose-
dependent reduction in cell viability (one-way ANOVA, 
p < 0.0001, F = 193.6, df = 18). After ANOVA, the indi-
vidual groups were subsequently analyzed using Bonfer-
roni multiple comparisons. The strongest toxic effect was 
found using Aβ4-42, AβpE3-42 and Aβ1-42 followed by Aβ4-40 
(compared to vehicle control; p < 0.0001). Aβ4-38 was only 
toxic at 10 μM. The same was true using a reverse Aβ42-1 
as an additional control. No significant difference was 
observed between Aβ1-42, AβpE3-42 and Aβ4-42. At 1 μM, 
there was a difference in the toxicity between Aβ4-42 
and Aβ4-40. At 5 μM, Aβ1-42 (p < 0.0001) and Aβ4-42 
(p < 0.001) were more potent than Aβ4-40. The same was 
found at 10 μM comparing Aβ1-42 (p < 0.0001) and Aβ4-42 
(p < 0.0001) with Aβ4-40 (Fig. 3b). Phase contrast images of 
Aβ-treated cells are shown in the supplement (Fig. S4).
N-truncated Aβ variants induce working memory deficits
In vivo effects were studied by intraventricular injection of 
freshly prepared 50 pmol Aβ4-38, Aβ4-40, Aβ4-42, AβpE3-42 and 
Aβ1-42 into wildtype mouse brain. Working memory was 
assessed using Y-maze (Fig. 3c). There was a significant 
treatment effect (one-way ANOVA, p < 0.001, F = 19.98, 
df = 6). After ANOVA, the individual groups were then 
analyzed using Bonferroni multiple comparisons. The alter-
nation rate was significantly reduced after injection of Aβ4-40 
(p < 0.01) and Aβ4-42 (p < 0.01) reaching chance level. 
Mice injected with Aβ4-38 behaved like vehicle controls and 
learned well.
Fig. 3  Cellular toxicity of N-truncated Aβ peptides. a Freshly pre-
pared Aβ4-38, Aβ4-40,Aβ4-42, AβpE3-42 and Aβ1-42 rapidly formed sta-
ble aggregates. All peptides displayed dimeric oligomers and mono-
mers under reducing conditions, while Aβ1-42, AβpE3-42 and Aβ4-42 
also developed SDS-stable tri- or tetrameric oligomers. Aged Aβ1-42, 
AβpE3-42 and Aβ4-42 peptides retained this pattern and exhibited in 
addition higher molecular weight aggregates. SDS-PAGE Western 
blot of Aβ peptides using the polyclonal antiserum 24311. b In vitro 
toxicity with short-term exposure. Primary neurons were treated with 
Aβ peptides at different concentrations and analyzed by a cell toxicity 
assay. Aβ1-42 AβpE3-42 and Aβ4-42 demonstrated comparable toxicity 
profiles followed by Aβ4-40. Aβ4-38 was only toxic at 10 μM. No tox-
icity was observed with vehicle control and reverse Aβ42-1. c In vivo 
toxicity of short-term exposure in wildtype mouse brain. Working 
memory was assessed after intraventricular injection of Aβ4-38, Aβ4-40, 
Aβ4-42, AβpE3-42 and Aβ1-42 as well as vehicle and reverse peptide con-
trol. Mice injected with Aβ4-40, Aβ4-42 AβpE3-42 and Aβ1-42 performed 
at chance level and showed a significant and robust deficit in work-
ing memory. Mice treated with Aβ4-38 demonstrated normal working 
memory. The same is true for the reverse peptide Aβ42-1 and vehicle 
control. One-way analysis of variance (ANOVA) followed by Bonfer-
roni multiple comparisons. ***p < 0.001
▸
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Aβ4-42 expression in Tg4-42 mice
In order to analyze the effect of chronic exposure of Aβ4-42 
in mouse brain, the Tg4-42 transgenic mouse line was 
developed. The transgene drives the neuronal expression 
of human Aβ4-42 fused to the murine thyrotropin releas-
ing hormone (TRH) signal peptide under the control of the 
Thy-1 promoter (Fig. 4a). The fusion peptide routes Aβ4-42 
through the secretory pathway enabling its extracellular 
release [68]. After pronuclear injection, eight transgenic 
founder lines were obtained and crossed with C57BL/6 J 
wildtype mice. Offspring from four of the successfully 
breeding founders were further examined by RT-PCR in 
order to identify the line with the highest expression level. 
Line 2 showed the highest expression level of the transgene 
relative to the other three lines (Fig. 4b; unpaired t tests, 
p < 0.05 line 2 versus line 3 and 4; p < 0.01 line 2 versus 
line 1). No significant differences in transgene levels were 
Fig. 4  Analysis of transgenic mice expressing Aβ4-42. a Scheme of 
transgene expression vector with THY1 promoter, signal peptide of 
pre-pro-thyrotropin releasing hormone (TRH), Aβ4-42 and THY1 3′ 
sequences. b Quantitative RT-PCR analysis of four different trans-
genic mouse lines producing Aβ4-42 showing variable transgene 
expression levels. Line 2 exhibited significantly the highest transgene 
expression (p < 0.01 unpaired t test compared to the other lines). This 
line was chosen for further breeding and renamed Tg4-42. c Western 
blot analysis of whole brain TBS lysates (40 μg total protein loaded) 
using pan-Aβ antibody 4G8 of 5-month-old hemizygous Tg4-42 
mice and a wildtype control. d, o–n Immunohistochemical staining 
profile of Tg4-42 mice expressing Aβ4-42. d Abundant intraneuronal 
Aβ immunoreactivity was found in the CA1 pyramidal cell layer of 
the hippocampus in 3-month-old hemizygous Tg4-42 mice (poly-
clonal antiserum 24311). Aβ42 immunostaining in CA1 at 3 e, 8 f and 
12 g months of age in hemizygous Tg4-42 mice with an age-depend-
ent reduction in positive cells. Other brain regions with Aβ42 staining 
were occipital cortex (h), piriform cortex i, striatum j and superior 
colliculus k. In addition, increased astrogliosis with GFAP staining 
l and microgliosis with IBA1 staining n was observed as early as 
2 months of age in hemizygous Tg4-42 mice. No significant astro and 
microgliosis were seen in wildtype (WT) controls (GFAP m, IBA1 
o). Scale bar in d 100 μm (d, k–o); scale bar in g: 50 μm (e–j)
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identified between lines 1, 3 and 4. As a result, mouse line 
2 was selected for further characterization and renamed 
Tg4-42. Protein expression was assessed using Western 
blot of Tg4-42 mouse brain (Fig. 4c).
Tg4-42 brain sections showed strong immunoreactiv-
ity predominantly in the CA1 region of the hippocampus 
beginning at the age of 2 months (Fig. 4d). CA1 Aβ expres-
sion declined during aging (Fig. 4d–g) due to neuron loss 
in CA1 (Fig. 5d). No difference was detected in Aβ expres-
sion between the polyclonal antiserum 24311 recogniz-
ing pan-Aβ and the Aβ42-specific antiserum (Fig. 4d, e). 
Other brain regions with Aβ42 staining were occipital cor-
tex (Fig. 4h), piriform cortex (Fig. 4i), striatum (Fig. 4j) 
and superior colliculus (Fig. 4k). Reactive microglia and 
astroglia demonstrated hippocampal neurodegeneration 
beginning at 2 months of age with no gliosis in wildtype 
littermate control mice (Fig. 4l–o).
Long-term exposure to N-truncated Aβ4-42 induces neuron 
loss
Obvious age- and dose-dependent neuron loss was seen 
in the hippocampus CA1 region of aged hemizygous 
and homozygous Tg4-42 mice (Fig. 5a–c, g) (one-way 
ANOVA, p = 0.001, F = 39.07; df = 2). Hemizygous 
Tg4-42 showed a 38 % neuron loss (mean = 178,000, 
SEM ± 9,083; p = 0.01) that was even more pro-
nounced in homozygous Tg4-42 mice with a 66 % decline 
(mean = 97,600, SEM ± 14,300, p = 0.001) compared 
to WT controls (mean = 282,700, SEM ± 15,670) at 
Fig. 5  Age- and dose-dependent neuron loss in hippocampus in Tg4-
42 mice. DAPI staining (a–c) revealed a loss in neuron number in 
the CA1 layer of the hippocampus at the age of 8 months between 
hemizygous b Tg4-42 and a age-matched WT mice. c A more pro-
nounced neuron loss was apparent in homozygous Tg4-42 mice. d–f 
Synaptophysin staining showed an altered synaptic patterning in the 
CA3 region of the hippocampus in hemizygous and more pronounced 
in homozygous Tg4-42 mice at the age of 8 months. g Quantification 
using unbiased stereology. Scale bars a–c 100 μm; d–f 50 μm; one-
way analysis of variance (ANOVA) followed by Bonferroni multiple 
comparisons. *p < 0.05, **p < 0.01
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8 months of age (Fig. 5g). Hemizygous 12-month old Tg4-
42 mice (mean = 144,100, SEM ± 9,540) displayed a 49 % 
neuron loss compared to same age WT (mean = 291,100, 
SEM ± 37,530) controls (Fig. 5g). Between 8 and 
12 months, the neuron loss in hemizygous mice increased 
by 23 %. At 3 months of age, no difference in the num-
ber of neurons was observed between hemizygous Tg4-42 
(mean = 309,600, SEM ± 17,570) mice and wildtype lit-
termates (mean = 304,800, SEM ± 12,560). The striatum 
was unaffected and did not show any significant neuron 
loss in 8-month-old Tg4-42hom mice (Fig. S5) supporting 
a primary role of the hippocampus for the spatial refer-
ence memory deficits in the Tg4-42 mouse model. Synap-
tophysin staining showed an altered synaptic patterning in 
the CA3 region of the hippocampus reflecting a possible 
network disturbance of neurons that are directly linked to 
the CA1 area. This synaptic alteration was seemingly more 
pronounced in homozygous as compared to hemizygous 
Tg4-42 mice at the age of 8 months (Fig. 5d–f).
Long-term exposure to N-truncated Aβ4-42 induces spatial 
memory deficits
Spatial reference memory was assessed in wildtype (WT), 
hemizygous and homozygous Tg4-42 mice, expressing 
Aβ4-42, using the Morris water maze. Hemizygous Tg4-42 
mice were tested at 3, 8 and 12 months of age in compari-
son to WT mice. In addition, homozygous Tg4-42 (Tg4-
42hom) mice were tested at 3 and 8 months of age. First, 
mice performed cued training with a marked platform to 
familiarize with the pool and to rule-out effects from pos-
sible motor or sensory deficits. WT, Tg4-42 and Tg4-42hom 
mice showed progressively decreased escape latencies at 
all ages tested (data not shown). The cued training revealed 
that all mice had intact vision and the appropriate motor 
abilities to swim.
Twenty-four hours after the cued training, mice were 
subjected to acquisition training in order to test their learn-
ing abilities to find the location of a submerged platform 
by using distal and proximal cues. Across the 5 days of 
acquisition the animals, irrespective of genotype and 
age, showed a significant decrease in the escape latencies 
(Fig. 6a–c) and the path lengths (data not shown) to reach 
the hidden platform (two-way repeated measures ANOVA, 
main effect of days: Escape latency: F (4,320) = 26.920; 
p < 0.001; Path length: F (4,320) = 28.148; p < 0.001). In 
contrast, no changes in the swimming speed of the animals 
were evident over the 5 days (Fig. 6d–f, two-way repeated 
measures ANOVA, F (4,320) = 0.596; p < 0.666). There 
was a significant main effect of the factor age on both 
escape latencies (two-way repeated measures ANOVA, F 
(2,80) = 3.982; p = 0.022) and the path lengths (two-way 
repeated measures ANOVA F(2,80) = 4.278; p = 0.017), 
whereas swimming speed was not significantly affected 
by the age of the animals (two-way repeated measures 
ANOVA F (2,80) = 2.550; p = 0.084).
These results suggest that younger animals performed 
superior in comparison to older animals. There were no 
age-related motor deficits as the swimming velocity was 
not different at all ages.
We also found a significant main effect of genotype for 
escape latencies (two-way repeated measures ANOVA, F 
(2,80) = 4.905; p = 0.010) and a trend for a significant 
difference for path lengths (two-way repeated measures 
ANOVA F(2,80) = 3.027; p = 0.054). In contrast, no sig-
nificant main effect of genotype was found for the swim-
ming speed readout (two-way repeated measures ANOVA, 
F (2,80) = 1.238; p = 0.296). These results suggest that 
Aβ4-42 expression in the mouse impairs spatial learning in 
the Morris water maze. No significant genotype x age inter-
action was found (two-way repeated measures ANOVA, 
Escape latency: F (2,80) = 0.718; p = 0.491; Path length: 
F (2,80) = 0.297; p = 0.744).
Twenty-four hours after the last acquisition trial, a probe 
trial was performed to assess spatial reference memory. At 
3 months of age, WT,Tg4-42 and Tg4-42hom mice displayed 
a significant preference for the target quadrant, as indicated 
by the percentage time spent in different quadrants of the 
pool (Fig. 7a, two-way ANOVA, p < 0.0001, F = 29.12, 
df = 3 for quadrants; WT: p < 0.001 target versus left quad-
rant, p < 0.0001 target versus right and opposite quadrant; 
Tg4-42: p < 0.0001 target versus left, p < 0.001 target ver-
sus right and opposite quadrant; Tg4-42hom: p < 0.001 tar-
get versus left and opposite quadrant, p < 0.01 target versus 
right quadrant; two-way ANOVA, p = 0.5942, F = 0.7710, 
df = 6 for interaction between quadrants and genotype). 
No quadrant preference was found for the 8-month-old 
homozygous Tg4-42 mice, while WT and Tg4-42 mice still 
demonstrated significant preference for the target quadrant 
at that time point (Fig. 7b, two-way ANOVA, p < 0.0001, 
F = 28.80, df = 3 for quadrants; WT: p < 0.0001 target 
versus all other quadrants; Tg4-42: p < 0.0001 target versus 
all other quadrants; Tg4-42hom: p > 0.05 target versus all 
other quadrants; two-way ANOVA, p = 0.0049, F = 3.267, 
df = 6 for interaction between quadrants and genotype). 
Twelve-month-old WT mice spent a significant higher 
percentage of time in the target quadrant in comparison to 
the other quadrants. However, 12-month-old Tg4-42 mice 
displayed no significant preference for the target quadrant 
indicating a robust deficit in spatial reference memory 
(Fig. 7c, two-way ANOVA, p < 0.0001, F = 15.73, df = 3 
for quadrants WT: p < 0.001 target versus left quadrant, 
p < 0.0001 target versus right and opposite quadrant; Tg4-
42: p > 0.05 target versus all other quadrants; two-way 
ANOVA, p = 0.0371, F = 2.955, df = 3 for interaction 
between quadrants and genotype). Swimming speed did not 
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differ during the probe trial between the groups or the dif-
ferent ages tested (Fig. 7a–c). A multivariate ANOVA per-
formed on target versus opposite quadrant preference ratios 
yielded a main effect of the factor genotype (MANOVA, F 
(2,75) = 5.682; p = 0.005) but no main effect of the fac-
tor age (MANOVA, F (2,75) = 1.367; p = 0.261). How-
ever, there was a significant genotype x age interaction for 
the readout preference ratio (MANOVA, F (2,75) = 4.204; 
p = 0.019). These results suggest that the detrimental 
effects of Aβ4-42 expression on spatial learning in the mouse 
aggravates in the course of aging.
In sum, the results of the acquisition phase and the probe 
trial suggest that Aβ4-42 expression in the mouse impairs 
spatial learning in the Morris water maze as reflected by the 
absence of a preference for the target quadrant as compared 
to the remaining quadrants during the probe trial. This 
spatial learning deficit is much more pronounced in old as 
compared to young Tg4-42 mice.
Discussion
In vitro and in vivo analysis of amyloid deposits in AD 
revealed N- and C-terminal variants of the Aβ peptide 
[33, 35, 48]. Masters et al. [33] discovered that the major-
ity (64 %) of the peptides in amyloid plaques of AD begin 
with a phenylalanine residue corresponding to position 
4 of the full-length sequence. Moreover, they detected 
dimeric and tetrameric (termed A8 and A16, respectively) 
Aβ aggregates from the HPLC separations of plaques 
from AD having the same ragged NH2-terminal ends. The 
importance of Aβ4-42 was later supported by showing that 
Aβ4-42 represents a dominant fraction in the hippocam-
pus and cortex of AD patients using immunoprecipitation 
and mass spectrometry [47]. In addition, Lewis et al. [31] 
reported that Aβ4-42 is a relatively abundant species in AD, 
aged controls and vascular dementia patients. Other groups 
identified Aβ11-42 as the only N-truncated species [41]. 
Fig. 6  Spatial learning was 
assessed using acquisition train-
ing of the Morris water maze. 
Heterozygous Tg4-42 mice and 
wildtype (C57BL/6 J) littermate 
controls were tested at a 3, b 8 
and c 12 months of age. In addi-
tion, homozygous Tg4-42 mice 
(Tg4-42hom) were assessed at 3 
and 8 months. Each group was 
sex- and age-matched and con-
tained 10–15 animals. Animals 
tested underwent acquisition 
training to learn to use distal 
and proximal cues to navigate a 
direct path to a hidden platform. 
a–c Escape latencies decreased 
progressively over 5 days of 
training for wildtype, Tg4-42 
and Tg4-42hom. Swimming 
speed was not affected in all 
mice tested. m age in months
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Mori and colleagues described the presence of Aβ peptides 
(15–20 % of the total Aβ) bearing a pyroglutamate residue 
at the N-terminus. By using pyroglutamate amino pepti-
dase, they were able to unravel the amino acid terminal, 
which is blocked by the lactam ring and thus resistant to 
any other peptidase for Edman sequencing used in previous 
reports [37]. Since then, the interest in dissecting the tem-
poral and spatial deposition of pyroglutamate Aβ increased. 
Saido et al. [54] showed by immunohistochemical and bio-
chemical means that AβpE3 is present in equivalent or larger 
amounts than full-length Aβ in senile plaques. This was 
further confirmed by another study on water-soluble Aβ 
Fig. 7  Memory deficits in aged Tg4-42 mice shown in the probe 
trial of the Morris water maze. Hemizygous Tg4-42 mice and 
WT (C57BL/6 J) littermate controls were tested at a 3, b 8 and c 
12 months of age. In addition, homozygous Tg4-42 (Tg4-42hom) 
mice were assessed at 3 and 8 months. Each group was sex- and 
age-matched and contained 10–15 mice. The probe trial was given 
at the end of the learning phase (acquisition training) to assess spa-
tial reference memory. Quadrant preference and swimming speed for 
the first 30 s of the probe trial were analyzed. a Tg4-42, Tg4-42hom 
and WT mice showed no impairment in spatial reference memory at 
3 months of age. Both groups spent a significant greater percentage 
of the time in the target quadrant. b The probe trial revealed signifi-
cantly reduced learning behavior for Tg4-42hom mice at 8 months of 
age as they showed no preference for the target quadrant. In contrast, 
hemizygous Tg4-42 and WT mice had no learning deficits at this age. 
c At 12 months of age, hemizygous Tg4-42 mice showed no quadrant 
preference revealing an impaired spatial reference memory. How-
ever, WT mice still learned, as they had a significant preference for 
the target quadrant. a–c No differences in swimming speed between 
WT, Tg4-42 and Tg4-42hom were detected at any tested age. T target 
quadrant, L left quadrant, R right quadrant, O opposite quadrant, m 
age in months. Quadrant preference: Two-way analysis of variance 
(ANOVA) followed by Bonferroni multiple comparisons. Swimming 
speed: unpaired t-test. ***p < 0.001; **p < 0.01
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demonstrating the presence of AβpE3-42 in AD and Down 
syndrome (DS) as a dominant fraction [52]. In line with the 
previous findings, testing extracts from AD and DS fron-
tal cortex using ELISA revealed that levels of AβpE3 and 
isomerized Aβ species ending at amino acid 42 were higher 
than those ending with amino acid 40 [15, 18]. This was 
further confirmed by the finding that AβpE3-42 constituted 
25 % of the total Aβx-42 in plaques of AD brains [15]. It was 
reported that unmodified Aβ1-40 and Aβ1-42 can be modified 
into AβpE3 after being injected into rat brain indicating that 
rat brains harbor the enzymes required for N-terminal trun-
cation and pyroglutamate formation [63]. Analysis of water 
soluble Aβ in AD, DS as well as non-demented elderly 
brain specimens indicated the presence of Aβ1-42, AβpE3-42 
and AβpE11-42. Russo et al. [53] showed that cases with a 
PS1 mutations develop a higher ratio of water-soluble 
AβpE3-42 and AβpE11-42 to full-length Aβ1-42 in comparison 
to sporadic AD cases.
In addition, biochemical studies showed that Aβ pep-
tides isolated from AD brains were post-translationally 
modified by isomerization and racemization [26, 38]. 
Isomerized Aβ at the seventh amino acid was suggested to 
comprise a major fraction of Aβ in neuritic plaques [50]. 
Both modifications have been shown to accelerate peptide 
aggregation and fibril formation [38, 62, 64]. Other modi-
fications include metal-induced oxidation [11] or phospho-
rylation [24, 25, 36].
N-terminal deletions enhance Aβ aggregation and toxic-
ity in relation to full-length Aβ [45]. Pike et al. [45] com-
pared Aβ peptides with initial residues at positions 1, 4, 8, 
12, and 17 and ending with residue 40 or 42 using circular 
dichroism spectra. They reported a predominant β-sheet 
conformation, fibrillar morphology under transmission 
electron microscopy, and significant toxicity in cultures of 
rat hippocampal neurons. Our data extend these observa-
tions and show that soluble aggregates have specific fea-
tures responsible for their neurotoxicity. We demonstrated 
that all five Aβ variants studied (Aβ4-38, Aβ4-40 Aβ4-42, Aβ1-42 
and AβpE3-42) are unstructured in the monomeric state. 
However, upon heating the Aβ variants showed a high pro-
pensity to form folded structures, in particular the three 
most toxic variants AβpE3-42, Aβ1-42 and Aβ4-42. In addition, 
monomeric Aβ4-42 and AβpE3-42 were rapidly converted 
to soluble aggregated species. The soluble aggregates are 
capable of converting to ThT-reactive fibrillar aggregates 
with Aβ4-42 and AβpE3-42 showing significant ThT-reactivity 
already during the nucleation phase of aggregation. The 
observation that the propensity of Aβ4-42 to form aggregates 
is more pronounced than the N-terminally intact Aβ1-42 pep-
tide suggests that Aβ4-42 aggregation may precede Aβ1-42 
aggregation in the in vivo condition.
Small, soluble Aβ1-42 oligomers ranging in size from 
dimers to dodecamers have been found as key drivers of 
neurotoxicity in vitro and in vivo [6, 28, 30, 43, 61, 71]. 
Increased C-terminal length of Aβ (from Aβ1-40 to Aβ1-42) 
enhances aggregation, early deposition and promotes the 
toxicity of Aβ [2, 19, 45] suggesting that Aβ1-42 aggregates 
represent the major toxic factor [3]. At the same time, there 
is increasing evidence that N-truncated species, such as 
AβpE3-42, may contribute to AD-typical behavioral deficits 
[20, 56]. The increased hydrophobicity of the N-terminal 
part upon removal of the first three residues may influence 
the interaction of Aβ aggregates with cellular membranes 
and modulate its cytotoxic properties. Here we show evi-
dence that short-term exposure to aggregated Aβ4-x peptides 
triggers neuron loss in primary cortical cultures, with the 
strongest effect for Aβ4-42 followed by Aβ4-40 and Aβ4-38. 
Intracerebral infusion of Aβ1-42 and AβpE3-42 oligomers has 
been repeatedly shown to affect hippocampus-dependent 
behavior assessed by working memory behavioral testing 
[6, 71]. Our studies are well in line with these observations. 
We demonstrate that Aβ4-40 and Aβ4-42, but not Aβ4-38, 
have comparable detrimental effects using the same con-
centration as previously employed for Aβ1-42 and AβpE3-42 
oligomers [71].
Levels of N-truncated and modified Aβ are known to 
vary between AD mouse models. In Tg2576 mice, trun-
cated and modified Aβ isoforms do not appear before 
1 year of age and comprise approximately 5 % of total Aβ 
[22]. AβpE3 and other modified forms of Aβ were reported 
to be absent in APP23 mice until almost 2 years of age 
[27] or low in PS2APP mice [13]. Using another approach, 
Maeda and colleagues demonstrated that the localization 
and abundance of [11C]PIB autoradiographic signals were 
closely associated with AβpE3 plaques in AD and different 
APP transgenic mouse brains. This observation suggests 
that the [11C]PIB-PET retention signal depends on the 
accumulation of specific Aβ subtypes [32]. Interestingly, 
significant brain-area-specific neuron loss develops in both 
APP/PS1KI and 5XFAD mice [4, 7–9, 21, 42]. The TBA42 
mouse model, like the TBA2, TBA2.1 and TBA2.2 mod-
els [1, 68], expresses Aβ3Q-42 starting with an N-terminal 
glutamine (Q) residue at position three of Aβ. Glutamine 
was used instead of the naturally occurring glutamate since 
it is a better substrate for both the spontaneous and enzy-
matically catalyzed conversion of Aβ3-42- into AβpE3-42 [10]. 
The degree of conversion was not determined in the TBA2, 
TBA2.1 and TBA2.2 mice. Therefore, unmodified N-trun-
cated Aβ3-42 could also contribute to the observed pathol-
ogy and behavioral phenotype. Using mass spectrometric 
analysis, we could previously demonstrate that 5XFAD 
mice already exhibit high amounts of AβpE3-42 and other Aβ 
isoforms. Besides Aβ1-42, the following peptides were also 
identified in 5XFAD mice, in order of abundance: Aβ1-40, 
Aβ4-42, Aβ5-42, AβpE3-42 and Aβ3-42. The appearance of an 
exceedingly heterogeneous population of N-truncated and 
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modified Aβ peptides in 5XFAD mice is in line with previ-
ous observations made in the APP/PS1KI mouse model [7].
In order to investigate the long-lasting neurotoxic 
effect of Aβ4-42, we generated transgenic mice expressing 
Aβ4-42 (Tg4-42 mouse line). Tg4-42 mice develop severe 
hippocampus neuron loss and spatial reference memory 
deficits. These data are corroborated by previous mouse 
models expressing full-length mutant APP. For example, 
APP/PS1KI mice exhibit neuron loss in the CA1 region of 
the hippocampus [4, 7], the frontal cortex [8], and in dis-
tinct cholinergic nuclei [9]. This model is characterized 
by age-dependent accumulation of heterogeneous N-ter-
minal truncated Aβ peptides with Aβ4-42 being one of the 
most abundant variants. In 5XFAD, another mouse model 
expressing mutant APP and PS1 [42], a heterogeneous mix-
ture of full-length, N-truncated and modified Aβ peptides, 
including Aβ4-42, were found [70]. The pathological events 
observed in the APP/PS1KI and 5XFAD mouse models 
might be at least partly triggered by N-terminal truncated 
Aβx-42. Neuron loss and an associated severe neurologi-
cal phenotype were found in a transgenic mouse model 
expressing only N-truncated AβpE3-42 [69], supporting the 
concept that N-truncated Aβ is neurotoxic. At present it is 
unclear whether N-truncated Aβ starting at position four 
is derived from the full-length Aβ1-42 or directly from the 
amyloid precursor protein. However, once it is generated it 
might actively participate in the amyloid cascade.
The Tg4-42 model represents the first mouse model 
expressing exclusively N-truncated Aβ4-42. At 8 months 
homozygous Tg4-42 mice showed severe neuron loss in the 
CA1 region (66 %) accompanied by impaired spatial mem-
ory. In spite of a 38 % neuron loss in the CA1 at 8 months 
of age hemizygous Tg4-42 mice demonstrated no deficits 
in learning. Broadbent et al. [5] examined the relationship 
between hippocampal lesion size and spatial memory in 
rats. Spatial memory impairment started after bilateral dor-
sal hippocampal lesions that encompassed 30–50 % total 
volume, and as lesion size increased from 50 to 100 % 
of total hippocampal volume, performance was similarly 
impaired. In addition, Moser et al. [40] claimed that only 
20–40 % of the total hippocampus is required for efficient 
spatial learning. These findings show that the hippocampus 
is important for spatial memory albeit a significant neuron 
loss can be compensated. Our findings are in good agree-
ment with these observations as a 38 % neuron loss in the 
CA1 of the hippocampus in 8-month-old hemizygous Tg4-
42 mice has no consequence on spatial reference memory 
performance. However, homozygous Tg4-42 mice with a 
66 % neuron loss demonstrate significant impaired spatial 
learning in the Morris water maze. Both the age-dependent 
deficits in spatial reference memory and the severe hip-
pocampal neuron loss in homozygous Tg4-42 mice are 
compatible with AD-typical changes.
The mode of Aβ and in particular Aβ4-42 toxicity is cur-
rently not clear. It has been suggested that membrane per-
meabilization by amyloid oligomers may initiate a com-
mon group of downstream pathologic processes, including 
intracellular calcium dyshomeostasis, production of reac-
tive oxygen species, altered signaling pathways, and mito-
chondrial dysfunction that represent key effectors of cellu-
lar dysfunction and cell death [12]. Naturally secreted Aβ 
oligomers may directly impair synaptic function and have 
been shown to block hippocampal long-term potentiation 
(reviewed in [14]). Recently, it was demonstrated that Aβ1-42 
oligomers trigger cell surface receptor clustering near or 
within synapses, leading to mGluR5 dysfunction [49]. Our 
finding that soluble and aggregated Aβ4-42 species are as 
toxic as Aβ1-42 suggests that similar mechanisms might be 
active in the case of Aβ4-42 aggregates.
The controversy among different studies regarding the 
predominant species and their contribution to the pathology 
of AD might reflect differences in the brain regions ana-
lyzed, imbalances in age and disease stages of the recruited 
cases, different protocols utilized and the characteristics 
of the peptides under investigation. Our current and pre-
viously published data demonstrate that both Aβ peptides 
Aβ4-42 and AβpE3-42 are likely playing a dominant role in 
triggering AD pathology. Which one of these two peptides 
might be accumulating first in AD is presently unclear 
as no antibody recognizing the N-terminus of Aβ4-42 
is available. In the present study, we revealed actions of 
human Aβ4-42 in the mouse brain that are consistent with a 
role for Aβ4-42 in the pathogenesis of AD in humans. Sol-
uble Aβ4-42 aggregates triggered neuron death in primary 
cortical neurons and significantly affected the working 
memory phenotype in wildtype mice after intraventricu-
lar injection. Aβ4-42 aggregates showed a high aggregation 
propensity and stability. Finally, long-term exposure to 
Aβ4-42 induced neuron loss and behavioral deficits in trans-
genic Tg4-42 mice.
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